Before BMS’ offering, Roche’s PD-L1 inhibitor Tecentriq became the first checkpoint inhibitor to secure a subcutaneous approval from the FDA. Called Tecentriq Hybreza, the injection’s ...

for subcutaneous injection across approved nivolumab (Opdivo) indications for adult, solid tumors as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy ...

Vaccines protect babies and children from potentially life-threatening diseases. Widespread childhood vaccination has reduced or eliminated deadly diseases like polio and smallpox. Vaccines currently ...

IIT Bombay has developed needle-free shock syringes for painless, safe drug delivery, offering hope for a future without injection-related trauma. Tested on rats, it outperformed traditional needles ...

The Tennessee Department of Correction announced in a brief statement Friday it had "completed its revision of the lethal injection protocol, which will utilize the single drug pentobarbital." ...

HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 ...

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release. Nivolumab and ...

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors. The Food and Drug Administration (FDA) approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a ...

Human immunoglobulin G is administered subcutaneously at the same site within approximately 10 minutes after the subcutaneous injection of vorhyaluronidase alfa (genetical recombination).

HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 ...

The FDA has approved the subcutaneous formulation of nivolumab (Opdivo). This approval makes it the first and only subcutaneously administered PD-1 inhibitor. Subcutaneous nivolumab is approved in all ...

which helps reduce treatment administration from hours-long IV infusions to subcutaneous injections delivered in minutes. Sign up here. Reporting by Sneha S K and Sriparna Roy in Bengaluru ...